News

Boston Scientific recently reported its second-quarter 2026 results, showing sales of US$5,442 million and net income of US$907 million, alongside issuing a recall of its Rapid Refill Continuous Injection System and initiating a multi-year global restructuring plan aimed at cost efficiencies. While the company raised full-year 2026 net sales growth expectations to approximately 5.5%–6.5%, it also outlined a restructuring program costing up to US$800 million and targeting around US$500...

Recall driven attention on Boston Scientific stock Boston Scientific (BSX) is back in focus after a series of voluntary recalls for its CRE and CRE Pro Wireguided gastrointestinal devices, tied to potential sterile pouch breaches across widely distributed product lots. With more than 81,000 units cited in individual recall notices and a worldwide distribution footprint, the situation brings product quality controls, potential regulatory implications and timing before the upcoming earnings...

Boston Scientific recently initiated several voluntary Class II recalls of its CRE and CRE Pro Wireguided endoscopy devices worldwide due to potential sterile breaches in packaging, affecting tens of thousands of units across multiple size ranges. The recalls underscore the operational and regulatory risks inherent in Boston Scientific’s expanding minimally invasive device portfolio, especially as it integrates recent acquisitions and scales global distribution. We’ll now examine how these...

Johnson & Johnson expects U.S. physicians to perform the first procedures with the device this summer as it starts a phased commercial rollout.

Earlier in June 2026, the US Food and Drug Administration posted a Class II, firm-initiated recall of 9,750 Boston Scientific Orca sterile, single-use air/water and suction valves (lot 38400303, expiring January 20, 2029) after higher-than-expected reports of suction buttons sticking during gastrointestinal endoscopy procedures. The recall, which is ongoing and affects nationwide US distribution, highlights how even accessory devices can create operational and regulatory pressures for a...

Boston Scientific (NYSE:BSX) has initiated a nationwide recall of its Orca Single Use Air/Water and Suction Valves. The recall is voluntary and follows identification of a device malfunction affecting procedures across the United States. The action reflects a material operational event for the company, with implications for patient safety oversight. Boston Scientific is a major medical device company, so a recall tied to endoscopy accessories like the Orca Single Use Air/Water and Suction...

Boston Scientific (NYSE:BSX) has initiated two voluntary recalls of its LUX-Dx II arrhythmia detector and alarm devices. The recalls follow FDA enforcement reports citing failures in data collection and monitoring of critical cardiac events for certain patients. Issues include discrepancies in device programming interfaces that affect reliability of arrhythmia monitoring and treatment decisions. The recalls are ongoing and affect patients and clinicians in multiple regions, including the US...

Multiple securities class action lawsuits have been filed against Boston Scientific (NYSE:BSX), alleging misleading statements about the sustainability of U.S. electrophysiology growth. The cases focus on disclosures related to a key business segment and whether investors were given an accurate view of growth prospects. Several court ordered and attorney set deadlines are approaching for shareholders who may wish to participate in these actions. Boston Scientific is a large medical device...